Cargando…

Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA

BACKGROUND: Hypertrophic cardiomyopathy is defined as unexplained left ventricular (LV) hypertrophy (wall thickness ≥15 mm) and is prevalent in 0.2% of adults (1:500) in population‐based studies using echocardiography. Cardiac magnetic resonance imaging (MRI) allows for more accurate wall thickness...

Descripción completa

Detalles Bibliográficos
Autores principales: Massera, Daniele, McClelland, Robyn L., Ambale‐Venkatesh, Bharath, Gomes, Antoinette S., Hundley, W. Gregory, Kawel‐Boehm, Nadine, Yoneyama, Kihei, Owens, David S., Garcia, Mario J., Sherrid, Mark V., Kizer, Jorge R., Lima, Joao A. C., Bluemke, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507185/
https://www.ncbi.nlm.nih.gov/pubmed/30957681
http://dx.doi.org/10.1161/JAHA.119.012250
_version_ 1783416979422445568
author Massera, Daniele
McClelland, Robyn L.
Ambale‐Venkatesh, Bharath
Gomes, Antoinette S.
Hundley, W. Gregory
Kawel‐Boehm, Nadine
Yoneyama, Kihei
Owens, David S.
Garcia, Mario J.
Sherrid, Mark V.
Kizer, Jorge R.
Lima, Joao A. C.
Bluemke, David A.
author_facet Massera, Daniele
McClelland, Robyn L.
Ambale‐Venkatesh, Bharath
Gomes, Antoinette S.
Hundley, W. Gregory
Kawel‐Boehm, Nadine
Yoneyama, Kihei
Owens, David S.
Garcia, Mario J.
Sherrid, Mark V.
Kizer, Jorge R.
Lima, Joao A. C.
Bluemke, David A.
author_sort Massera, Daniele
collection PubMed
description BACKGROUND: Hypertrophic cardiomyopathy is defined as unexplained left ventricular (LV) hypertrophy (wall thickness ≥15 mm) and is prevalent in 0.2% of adults (1:500) in population‐based studies using echocardiography. Cardiac magnetic resonance imaging (MRI) allows for more accurate wall thickness measurement across the entire ventricle than echocardiography. The prevalence of unexplained LV hypertrophy by cardiac MRI is unknown. MESA (Multi‐Ethnic Study of Atherosclerosis) recruited individuals without overt cardiovascular disease 45 to 84 years of age. METHODS AND RESULTS: We studied 4972 individuals who underwent measurement of regional LV wall thickness by cardiac MRI as part of the MESA baseline exam. American Heart Association criteria were used to define LV segments. We excluded participants with hypertension, LV dilation (≥95% predicted end‐diastolic volume) or dysfunction (ejection fraction ≤50%), moderate‐to‐severe left‐sided valve lesions by cardiac MRI, severe aortic valve calcification by cardiac computed tomography (aortic valve Agatston calcium score >1200 in women or >2000 in men), obesity (body mass index >35 kg/m(2)), diabetes mellitus, and current smoking. Sixty‐seven participants (aged 64±10 years, 9% female) had unexplained LV hypertrophy (wall thickness ≥15 mm in at least 2 adjacent LV segments), representing 1.4% (1 in 74) participants, 2.6% of men and 0.2% of women. Prevalence was similar across categories of race/ethnicity. Hypertrophy was focal in 17 (25.4%), intermediate in 44 (65.7%), and diffuse in 5 (7.5%) participants. CONCLUSIONS: The prevalence of unexplained LV hypertrophy in a population‐based cohort using cardiac MRI was 1.4%. This may have implications for the diagnosis of patients with hypertrophic cardiomyopathy and will require further study.
format Online
Article
Text
id pubmed-6507185
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65071852019-05-13 Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA Massera, Daniele McClelland, Robyn L. Ambale‐Venkatesh, Bharath Gomes, Antoinette S. Hundley, W. Gregory Kawel‐Boehm, Nadine Yoneyama, Kihei Owens, David S. Garcia, Mario J. Sherrid, Mark V. Kizer, Jorge R. Lima, Joao A. C. Bluemke, David A. J Am Heart Assoc Original Research BACKGROUND: Hypertrophic cardiomyopathy is defined as unexplained left ventricular (LV) hypertrophy (wall thickness ≥15 mm) and is prevalent in 0.2% of adults (1:500) in population‐based studies using echocardiography. Cardiac magnetic resonance imaging (MRI) allows for more accurate wall thickness measurement across the entire ventricle than echocardiography. The prevalence of unexplained LV hypertrophy by cardiac MRI is unknown. MESA (Multi‐Ethnic Study of Atherosclerosis) recruited individuals without overt cardiovascular disease 45 to 84 years of age. METHODS AND RESULTS: We studied 4972 individuals who underwent measurement of regional LV wall thickness by cardiac MRI as part of the MESA baseline exam. American Heart Association criteria were used to define LV segments. We excluded participants with hypertension, LV dilation (≥95% predicted end‐diastolic volume) or dysfunction (ejection fraction ≤50%), moderate‐to‐severe left‐sided valve lesions by cardiac MRI, severe aortic valve calcification by cardiac computed tomography (aortic valve Agatston calcium score >1200 in women or >2000 in men), obesity (body mass index >35 kg/m(2)), diabetes mellitus, and current smoking. Sixty‐seven participants (aged 64±10 years, 9% female) had unexplained LV hypertrophy (wall thickness ≥15 mm in at least 2 adjacent LV segments), representing 1.4% (1 in 74) participants, 2.6% of men and 0.2% of women. Prevalence was similar across categories of race/ethnicity. Hypertrophy was focal in 17 (25.4%), intermediate in 44 (65.7%), and diffuse in 5 (7.5%) participants. CONCLUSIONS: The prevalence of unexplained LV hypertrophy in a population‐based cohort using cardiac MRI was 1.4%. This may have implications for the diagnosis of patients with hypertrophic cardiomyopathy and will require further study. John Wiley and Sons Inc. 2019-04-06 /pmc/articles/PMC6507185/ /pubmed/30957681 http://dx.doi.org/10.1161/JAHA.119.012250 Text en © 2019 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Massera, Daniele
McClelland, Robyn L.
Ambale‐Venkatesh, Bharath
Gomes, Antoinette S.
Hundley, W. Gregory
Kawel‐Boehm, Nadine
Yoneyama, Kihei
Owens, David S.
Garcia, Mario J.
Sherrid, Mark V.
Kizer, Jorge R.
Lima, Joao A. C.
Bluemke, David A.
Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA
title Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA
title_full Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA
title_fullStr Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA
title_full_unstemmed Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA
title_short Prevalence of Unexplained Left Ventricular Hypertrophy by Cardiac Magnetic Resonance Imaging in MESA
title_sort prevalence of unexplained left ventricular hypertrophy by cardiac magnetic resonance imaging in mesa
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507185/
https://www.ncbi.nlm.nih.gov/pubmed/30957681
http://dx.doi.org/10.1161/JAHA.119.012250
work_keys_str_mv AT masseradaniele prevalenceofunexplainedleftventricularhypertrophybycardiacmagneticresonanceimaginginmesa
AT mcclellandrobynl prevalenceofunexplainedleftventricularhypertrophybycardiacmagneticresonanceimaginginmesa
AT ambalevenkateshbharath prevalenceofunexplainedleftventricularhypertrophybycardiacmagneticresonanceimaginginmesa
AT gomesantoinettes prevalenceofunexplainedleftventricularhypertrophybycardiacmagneticresonanceimaginginmesa
AT hundleywgregory prevalenceofunexplainedleftventricularhypertrophybycardiacmagneticresonanceimaginginmesa
AT kawelboehmnadine prevalenceofunexplainedleftventricularhypertrophybycardiacmagneticresonanceimaginginmesa
AT yoneyamakihei prevalenceofunexplainedleftventricularhypertrophybycardiacmagneticresonanceimaginginmesa
AT owensdavids prevalenceofunexplainedleftventricularhypertrophybycardiacmagneticresonanceimaginginmesa
AT garciamarioj prevalenceofunexplainedleftventricularhypertrophybycardiacmagneticresonanceimaginginmesa
AT sherridmarkv prevalenceofunexplainedleftventricularhypertrophybycardiacmagneticresonanceimaginginmesa
AT kizerjorger prevalenceofunexplainedleftventricularhypertrophybycardiacmagneticresonanceimaginginmesa
AT limajoaoac prevalenceofunexplainedleftventricularhypertrophybycardiacmagneticresonanceimaginginmesa
AT bluemkedavida prevalenceofunexplainedleftventricularhypertrophybycardiacmagneticresonanceimaginginmesa